Five studies examined VTE risk in patients receiving SGLT2 inhibitors, including three meta-analyses,32, 34, 36a pooled analysis of RCTs,38and a systematic review.39These studies consistently reported no association between SGLT2 inhibitors and VTE or DVT. The gene discussed is SLC5A2; the disease is deep vein thrombosis.